U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2000
172
Substance Class Protein
Created
by admin
on Wed Apr 02 08:23:23 GMT 2025
Edited
by admin
on Wed Apr 02 08:23:23 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG4
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
8GZG754X6M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GEMTUZUMAB OZOGAMICIN (GENETICAL RECOMBINATION) [JAN]
JAN  
Preferred Name English
GEMTUZUMAB OZOGAMICIN
EMA EPAR   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
GEMTUZUMAB OZOGAMICIN [USAN]
Common Name English
GEMTUZUMAB OZOGAMICIN [MI]
Common Name English
CMC-676
Code English
GEMTUZUMAB OZOGAMICIN [JAN]
Common Name English
CMA-676
Code English
GEMTUZUMAB OZOGAMICIN [VANDF]
Common Name English
Gemtuzumab ozogamicin [WHO-DD]
Common Name English
MYLOTARG
Brand Name English
GEMTUZUMAB OZOGAMICIN RECOMBINANT
Common Name English
GEMTUZUMAB OZOGAMICIN [EMA EPAR]
Common Name English
GEMTUZUMAB OZOGAMICIN [ORANGE BOOK]
Common Name English
WAY-CMA-676
Code English
GEMTUZUMAB OZOGAMICIN [MART.]
Common Name English
gemtuzumab ozogamicin [INN]
Common Name English
GEMTUZUMAB OZOGAMICIN [PURPLE BOOK CDER]
Common Name English
CDP-771
Code English
L01XC05
Code English
Classification Tree Code System Code
EU-Orphan Drug EU/3/00/005
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
NDF-RT N0000175571
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
NCI_THESAURUS C129823
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
WHO-ATC L01XC05
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
EMA ASSESSMENT REPORTS MYLOTARG (REFUSED: LEUKEMIA, MYELOID, ACUTE)
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
NCI_THESAURUS C2333
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
LIVERTOX NBK548438
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
FDA ORPHAN DRUG 127899
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
Code System Code Type Description
MERCK INDEX
m5694
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
PRIMARY Merck Index
ChEMBL
CHEMBL1201506
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
PRIMARY
RXCUI
1294580
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
PRIMARY RxNorm
CAS
220578-59-6
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
PRIMARY
SMS_ID
100000089560
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
PRIMARY
WIKIPEDIA
Gemtuzumab ozogamicin
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
PRIMARY
LACTMED
Gemtuzumab Ozogamicin
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
PRIMARY
EVMPD
SUB20794
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
PRIMARY
DAILYMED
8GZG754X6M
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
PRIMARY
IUPHAR
6775
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
PRIMARY
NCI_THESAURUS
C1806
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
PRIMARY
FDA UNII
8GZG754X6M
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
PRIMARY
DRUG CENTRAL
4980
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
PRIMARY
DRUG BANK
DB00056
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
PRIMARY
INN
10315
Created by admin on Wed Apr 02 08:23:23 GMT 2025 , Edited by admin on Wed Apr 02 08:23:23 GMT 2025
PRIMARY
From To
1_22 1_96
1_143 1_199
1_257 1_317
1_363 1_421
2_22 2_96
2_143 2_199
2_257 2_317
2_363 2_421
1_130 3_218
2_130 4_218
1_222 2_222
1_225 2_225
3_23 3_92
3_138 3_198
4_23 4_92
4_138 4_198
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_293
N 2_293
Related Record Type Details
MYELOID CELL SURFACE ANTIGEN CD33
TARGET -> INHIBITOR
HIGH AFFINITY IMMUNOGLOBULIN GAMMA FC RECEPTOR I
TARGET -> AGONIST
Related Record Type Details
GEMTUZUMAB OZOGAMICIN
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO_ACID_SUBSTITUTION RESIDUE_SPECIFIC D;K Amount: OZOGAMICIN LYSINE 606387782B
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966